Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency.

Guevara-Aguirre J, Rosenbloom AL, Vasconez O, Martinez V, Gargosky SE, Allen L, Rosenfeld RG

The Journal of clinical endocrinology and metabolism1 Feb 1997Cited by 77 (Europe PMC)

PMID9024266DOI10.1210/jcem.82.2.3743PepBankPUB-09024266

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

15 results from studies that gave the peptide. 15 results from people.

01HumanNon-randomized trialEfficacy outcome
In GH receptor-deficient children, growth velocity did not differ between rhIGF-I dosage groups.
In plain wordsIn GH receptor-deficient children, growth speed did not differ between the two rhIGF-I doses.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeGrowth velocity by dose
Study
n = 22
Comparator
80 micrograms/kg twice daily
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
120 micrograms/kg twice daily · 2 yrAs given in this study (human).
Source sentences
Summary
Over 2 yr of rhIGF-I treatment, there were no differences in GV or in changes in height SD score, height age (HA), or BA between the two groups; a subgroup of six subjects at the higher dose followed for a third year continued at the second year GV.
1 context sentence(design, population, supporting numbers)
Summary · context
This report extends observations of rhIGF-I efficacy at two dosage levels [120 micrograms/kg BW twice daily (n = 15) and 80 micrograms/kg twice daily (n = 7)] over 2 yr, compares biochemical responses [serum IGF-I and IGF-binding protein-3 (IGFBP-3)] and their relationship to growth effects, and com…
Report a problemFND-0902426601
02HumanNon-randomized trialEfficacy outcome
In GH receptor-deficient children, height SD score changes did not differ between rhIGF-I dosage groups.
In plain wordsIn GH receptor-deficient children, height score changes did not differ between the two rhIGF-I doses.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeHeight SD score change by dose
Study
n = 22
Comparator
80 micrograms/kg twice daily
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
120 micrograms/kg twice daily · 2 yrAs given in this study (human).
Source sentences
Summary
Over 2 yr of rhIGF-I treatment, there were no differences in GV or in changes in height SD score, height age (HA), or BA between the two groups; a subgroup of six subjects at the higher dose followed for a third year continued at the second year GV.
1 context sentence(design, population, supporting numbers)
Summary · context
This report extends observations of rhIGF-I efficacy at two dosage levels [120 micrograms/kg BW twice daily (n = 15) and 80 micrograms/kg twice daily (n = 7)] over 2 yr, compares biochemical responses [serum IGF-I and IGF-binding protein-3 (IGFBP-3)] and their relationship to growth effects, and com…
Report a problemFND-0902426602
03HumanNon-randomized trialEfficacy outcome
In GH receptor-deficient children, height age changes did not differ between rhIGF-I dosage groups.
In plain wordsIn GH receptor-deficient children, height age changes did not differ between the two rhIGF-I doses.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeHeight age change by dose
Study
n = 22
Comparator
80 micrograms/kg twice daily
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
120 micrograms/kg twice daily · 2 yrAs given in this study (human).
Source sentences
Summary
Over 2 yr of rhIGF-I treatment, there were no differences in GV or in changes in height SD score, height age (HA), or BA between the two groups; a subgroup of six subjects at the higher dose followed for a third year continued at the second year GV.
1 context sentence(design, population, supporting numbers)
Summary · context
This report extends observations of rhIGF-I efficacy at two dosage levels [120 micrograms/kg BW twice daily (n = 15) and 80 micrograms/kg twice daily (n = 7)] over 2 yr, compares biochemical responses [serum IGF-I and IGF-binding protein-3 (IGFBP-3)] and their relationship to growth effects, and com…
Report a problemFND-0902426603
04HumanNon-randomized trialEfficacy outcome
In GH receptor-deficient children, bone age changes did not differ between rhIGF-I dosage groups.
In plain wordsIn GH receptor-deficient children, bone age changes did not differ between the two rhIGF-I doses.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeBone age change by dose
Study
n = 22
Comparator
80 micrograms/kg twice daily
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
120 micrograms/kg twice daily · 2 yrAs given in this study (human).
Source sentences
Summary
Over 2 yr of rhIGF-I treatment, there were no differences in GV or in changes in height SD score, height age (HA), or BA between the two groups; a subgroup of six subjects at the higher dose followed for a third year continued at the second year GV.
1 context sentence(design, population, supporting numbers)
Summary · context
This report extends observations of rhIGF-I efficacy at two dosage levels [120 micrograms/kg BW twice daily (n = 15) and 80 micrograms/kg twice daily (n = 7)] over 2 yr, compares biochemical responses [serum IGF-I and IGF-binding protein-3 (IGFBP-3)] and their relationship to growth effects, and com…
Report a problemFND-0902426604
05HumanNon-randomized trialEfficacy outcome
In GH receptor-deficient children, higher-dose rhIGF-I produced a greater percent mean body weight for height change than lower-dose treatment.
In plain wordsIn GH receptor-deficient children, weight relative to height changed more with higher-dose rhIGF-I than with lower-dose treatment.
Peptide
IGF-1 (mecasermin)
Outcome
IncreasePercent mean body weight for height by dose
Study
n = 22
Comparator
80 micrograms/kg twice daily
Outcome group
Body weight · Metabolic and weight
Studied dose
120 micrograms/kg twice daily · 2 yrAs given in this study (human).
Source sentences
Summary
The higher dose resulted in a greater change in percent MBWH.
1 context sentence(design, population, supporting numbers)
Summary · context
This report extends observations of rhIGF-I efficacy at two dosage levels [120 micrograms/kg BW twice daily (n = 15) and 80 micrograms/kg twice daily (n = 7)] over 2 yr, compares biochemical responses [serum IGF-I and IGF-binding protein-3 (IGFBP-3)] and their relationship to growth effects, and com…
Report a problemFND-0902426606
06HumanNon-randomized trialEfficacy outcome
In GH receptor-deficient children, near-normal trough IGF-I levels did not differ between rhIGF-I dosage groups.
In plain wordsIn GH receptor-deficient children, trough IGF-I levels were nearly normal and similar between the two rhIGF-I doses.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeTrough serum IGF-I by dose
Study
n = 22
Comparator
80 micrograms/kg twice daily
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
120 micrograms/kg twice daily · 2 yrAs given in this study (human).
Source sentences
Summary
There were no differences between dosage groups for serum IGF-I levels at baseline or the near-normal trough levels 12 h after rhIGF-I injection; these individual levels correlated with HA gain in yr 1 and 2.
1 context sentence(design, population, supporting numbers)
Summary · context
This report extends observations of rhIGF-I efficacy at two dosage levels [120 micrograms/kg BW twice daily (n = 15) and 80 micrograms/kg twice daily (n = 7)] over 2 yr, compares biochemical responses [serum IGF-I and IGF-binding protein-3 (IGFBP-3)] and their relationship to growth effects, and com…
Report a problemFND-0902426613
07HumanNon-randomized trialMechanism
In rhIGF-I-treated GHRD children, individual serum IGF-I levels correlated with height age gain.
In plain wordsIn children with GHRD receiving rhIGF-I, blood IGF-I levels were linked to height age gains.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableIGF-I level correlation with height age gain
Study
n = 22
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · 2 yrAs given in this study (human).
Source sentences
Summary
There were no differences between dosage groups for serum IGF-I levels at baseline or the near-normal trough levels 12 h after rhIGF-I injection; these individual levels correlated with HA gain in yr 1 and 2.
1 context sentence(design, population, supporting numbers)
Summary · context
This report extends observations of rhIGF-I efficacy at two dosage levels [120 micrograms/kg BW twice daily (n = 15) and 80 micrograms/kg twice daily (n = 7)] over 2 yr, compares biochemical responses [serum IGF-I and IGF-binding protein-3 (IGFBP-3)] and their relationship to growth effects, and com…
Report a problemFND-0902426614
08HumanNon-randomized trialEfficacy outcome
In GH receptor-deficient children, markedly low IGFBP-3 levels did not change significantly with rhIGF-I treatment.
In plain wordsIn GH receptor-deficient children, very low IGFBP-3 levels did not change significantly during rhIGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeIGFBP-3 treatment change
Study
n = 22
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · 2 yrAs given in this study (human).
Source sentences
Summary
IGFBP-3 levels were markedly low, with no changes of significance with treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
This report extends observations of rhIGF-I efficacy at two dosage levels [120 micrograms/kg BW twice daily (n = 15) and 80 micrograms/kg twice daily (n = 7)] over 2 yr, compares biochemical responses [serum IGF-I and IGF-binding protein-3 (IGFBP-3)] and their relationship to growth effects, and com…
Report a problemFND-0902426615
09HumanNon-randomized trialEfficacy outcome
In a higher-dose rhIGF-I subgroup, third-year growth velocity continued at the second-year rate.
In plain wordsIn children receiving higher-dose rhIGF-I, growth speed remained at the second-year rate during the third year.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeThird-year growth velocity
Study
n = 6
Comparator
Second year growth velocity
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
120 micrograms/kg twice daily · third yearAs given in this study (human).
Source sentences
Summary
Over 2 yr of rhIGF-I treatment, there were no differences in GV or in changes in height SD score, height age (HA), or BA between the two groups; a subgroup of six subjects at the higher dose followed for a third year continued at the second year GV.
1 context sentence(design, population, supporting numbers)
Summary · context
This report extends observations of rhIGF-I efficacy at two dosage levels [120 micrograms/kg BW twice daily (n = 15) and 80 micrograms/kg twice daily (n = 7)] over 2 yr, compares biochemical responses [serum IGF-I and IGF-binding protein-3 (IGFBP-3)] and their relationship to growth effects, and com…
Report a problemFND-0902426605
10HumanNon-randomized trialEfficacy outcome
Growth velocity was lower in rhIGF-I-treated GHRD than in GH-treated GHD during the reported years.
In plain wordsChildren with GHRD receiving rhIGF-I grew more slowly than children with GHD receiving GH.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseGrowth velocity versus GH treatment
Study
n: not reported in source
Comparator
GH-treated idiopathic GH deficiency
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · 2 yrAs given in this study (human).
Source sentences
Summary
GV in yr 1 and 2 for the entire group and in yr 3 for a subgroup were greater for GH-treated GHD (n = 11).
1 context sentence(design, population, supporting numbers)
Summary · context
This report extends observations of rhIGF-I efficacy at two dosage levels [120 micrograms/kg BW twice daily (n = 15) and 80 micrograms/kg twice daily (n = 7)] over 2 yr, compares biochemical responses [serum IGF-I and IGF-binding protein-3 (IGFBP-3)] and their relationship to growth effects, and com…
Report a problemFND-0902426607
11HumanNon-randomized trialEfficacy outcome
Height SD score change was smaller in rhIGF-I-treated GHRD than in GH-treated GHD.
In plain wordsHeight scores changed less in children with GHRD receiving rhIGF-I than in children with GHD receiving GH.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseHeight SD score versus GH treatment
Study
n: not reported in source
Comparator
GH-treated idiopathic GH deficiency
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · 2 yrAs given in this study (human).
Source sentences
Summary
The GHD group showed a greater change in SD score for height and HA, but did not differ from the rhIGF-I-treated GHRD group in the change in BA (delta BA) or delta HA/delta BA over 2 yr.
1 context sentence(design, population, supporting numbers)
Summary · context
This report extends observations of rhIGF-I efficacy at two dosage levels [120 micrograms/kg BW twice daily (n = 15) and 80 micrograms/kg twice daily (n = 7)] over 2 yr, compares biochemical responses [serum IGF-I and IGF-binding protein-3 (IGFBP-3)] and their relationship to growth effects, and com…
Report a problemFND-0902426608
12HumanNon-randomized trialEfficacy outcome
Height age change was smaller in rhIGF-I-treated GHRD than in GH-treated GHD.
In plain wordsHeight age changed less in children with GHRD receiving rhIGF-I than in children with GHD receiving GH.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseHeight age versus GH treatment
Study
n: not reported in source
Comparator
GH-treated idiopathic GH deficiency
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · 2 yrAs given in this study (human).
Source sentences
Summary
The GHD group showed a greater change in SD score for height and HA, but did not differ from the rhIGF-I-treated GHRD group in the change in BA (delta BA) or delta HA/delta BA over 2 yr.
1 context sentence(design, population, supporting numbers)
Summary · context
This report extends observations of rhIGF-I efficacy at two dosage levels [120 micrograms/kg BW twice daily (n = 15) and 80 micrograms/kg twice daily (n = 7)] over 2 yr, compares biochemical responses [serum IGF-I and IGF-binding protein-3 (IGFBP-3)] and their relationship to growth effects, and com…
Report a problemFND-0902426609
13HumanNon-randomized trialEfficacy outcome
Bone age change did not differ between rhIGF-I-treated GHRD and GH-treated GHD.
In plain wordsBone age changed similarly in children with GHRD receiving rhIGF-I and children with GHD receiving GH.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeBone age versus GH treatment
Study
n: not reported in source
Comparator
GH-treated idiopathic GH deficiency
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · 2 yrAs given in this study (human).
Source sentences
Summary
The GHD group showed a greater change in SD score for height and HA, but did not differ from the rhIGF-I-treated GHRD group in the change in BA (delta BA) or delta HA/delta BA over 2 yr.
1 context sentence(design, population, supporting numbers)
Summary · context
This report extends observations of rhIGF-I efficacy at two dosage levels [120 micrograms/kg BW twice daily (n = 15) and 80 micrograms/kg twice daily (n = 7)] over 2 yr, compares biochemical responses [serum IGF-I and IGF-binding protein-3 (IGFBP-3)] and their relationship to growth effects, and com…
Report a problemFND-0902426610
14HumanNon-randomized trialEfficacy outcome
The height age to bone age change ratio did not differ between rhIGF-I-treated GHRD and GH-treated GHD.
In plain wordsHeight age relative to bone age changed similarly with rhIGF-I in GHRD and GH in GHD.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeHeight age to bone age change ratio
Study
n: not reported in source
Comparator
GH-treated idiopathic GH deficiency
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · 2 yrAs given in this study (human).
Source sentences
Summary
The GHD group showed a greater change in SD score for height and HA, but did not differ from the rhIGF-I-treated GHRD group in the change in BA (delta BA) or delta HA/delta BA over 2 yr.
1 context sentence(design, population, supporting numbers)
Summary · context
This report extends observations of rhIGF-I efficacy at two dosage levels [120 micrograms/kg BW twice daily (n = 15) and 80 micrograms/kg twice daily (n = 7)] over 2 yr, compares biochemical responses [serum IGF-I and IGF-binding protein-3 (IGFBP-3)] and their relationship to growth effects, and com…
Report a problemFND-0902426611
15HumanNon-randomized trialEfficacy outcome
Percent mean body weight for height changed more in rhIGF-I-treated GHRD than in GH-treated GHD.
In plain wordsWeight relative to height changed more with rhIGF-I in GHRD than with GH in GHD.
Peptide
IGF-1 (mecasermin)
Outcome
IncreasePercent mean body weight for height versus GH
Study
n: not reported in source
Comparator
GH-treated idiopathic GH deficiency
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 2 yrAs given in this study (human).
Source sentences
Summary
There was a greater change in percent MBWH in GHRD.
1 context sentence(design, population, supporting numbers)
Summary · context
This report extends observations of rhIGF-I efficacy at two dosage levels [120 micrograms/kg BW twice daily (n = 15) and 80 micrograms/kg twice daily (n = 7)] over 2 yr, compares biochemical responses [serum IGF-I and IGF-binding protein-3 (IGFBP-3)] and their relationship to growth effects, and com…
Report a problemFND-0902426612

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.